# African American Cardiovascular pharmacogenetic CONsorTium (ACCOuNT): discovery and translation

> **NIH NIH U54** · NORTHWESTERN UNIVERSITY · 2020 · $130,256

## Abstract

The purpose of this implementation core is to assure that the discovery and translational findings of
ACCOuNT are implemented into practice as promptly, effectively, and broadly as possible. We propose
to approach this challenge of implementing ACCOuNT findings by applying tools of implementation
science and by drawing on existing approaches to pharmacogenomic implementation. We add to this
specific partners and approaches chosen to address barriers in the implementation of race specific
pharmacogenetics for African Americans. These include, for example, the geographic concentration of
many African Americans in urban cores and often specific neighborhoods and hospitals within those
cores, the higher rates of poverty, and hence reliance on Medicaid, among African Americans, and the
history, and unfortunate continuing reality, of reasons for distrust of the health care system among
African Americans. These provide important context for our choice of approaches and partners in
implementation.
Thus, the overall aim of the implementation core is to establish mechanisms to support implementation,
diffusion, and continuing evaluation and improvement of precision medicine in African Americans. We
will do this through the following aims: 1) Develop an Implementation Advisory Council (IAC) to work
with the discovery and translational project leaders and ACCOuNT cores to assess and address
implementation issues for projects that have been funded or are being considered for pilot funding both
prospectively and iteratively during the course of translation, and 2) Develop and disseminate
curriculum, workshops, and collaborative interactions for patients, physicians and policy-makers on the
use of race specific precision medicine in clinical care.
Through this core, we will develop a framework by which discoveries made through pharmacogenomics
association studies can be assess for impact in translational studies and ultimately can be brought into
clinical care within the context that benefits African American patients.

## Key facts

- **NIH application ID:** 9934883
- **Project number:** 5U54MD010723-05
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** DAVID O MELTZER
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $130,256
- **Award type:** 5
- **Project period:** — → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9934883

## Citation

> US National Institutes of Health, RePORTER application 9934883, African American Cardiovascular pharmacogenetic CONsorTium (ACCOuNT): discovery and translation (5U54MD010723-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9934883. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*